Early Echocardiography and ECG Changes Following Radiotherapy in Patients with Stage II-III HER2-Positive Breast Cancer Treated with Anthracycline-Based Chemotherapy with or without Trastuzumab-Based Therapy

Radu Valeriu Toma; Zgura Anca; Oana Gabriela Trifănescu; Laurenția Nicoleta Galeș; Antonia Ruxandra Folea; Loredana Stanca; Liviu Bîlteanu; Rodica M. Anghel

doi:10.12659/MSM.941754

20 September 2023 : Clinical Research

Early Echocardiography and ECG Changes Following Radiotherapy in Patients with Stage II-III HER2-Positive Breast Cancer Treated with Anthracycline-Based Chemotherapy with or without Trastuzumab-Based Therapy

Radu Valeriu Toma^{^A Study design/planning

^B Data collection/entry

^C Data analysis/statistics

^G Funds collection

" data-author="4365589">12ABCG}, Zgura Anca^1E, Oana Gabriela Trifănescu^{^A Study design/planning

" data-author="4365591">12A}, Laurenția Nicoleta Galeș^{^D Data interpretation

^*Corresponding author: [email protected]
^*Corresponding author: [email protected]
" data-author="4365592">12D*}, Antonia Ruxandra Folea^{^C Data analysis/statistics

^D Data interpretation

^E Preparation of manuscript

^F Literature analysis/search

" data-author="4365593">2CDEF}, Loredana Stanca^3B, Liviu Bîlteanu^{³Department of Preclinical Science, Faculty of Veterinary Medicine, University of Agronomic Sciences and Veterinary Medicine, Bucharest, Romania
⁴Laboratory of Molecular Nanotechnologies, National Institute for Research and Development in Microtechnologies, Voluntary, Romania

^A Study design/planning

^B Data collection/entry

^C Data analysis/statistics

^D Data interpretation

^E Preparation of manuscript

^F Literature analysis/search

" data-author="4365595">234ABCDEF}, Rodica M. Anghel^1A

DOI: 10.12659/MSM.941754

Med Sci Monit 2023; 29:e941754

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Supplementary Table 10 The value (in%) of the first drop in ejection fraction (EF), as well as the period (in days) from the start of therapy (CHT – chemotherapy, RT – radiotherapy, TT – targeted therapy) to the time of recording this first variation.

		CHT		TT		RT
		First EF drop	Time period	First EF drop	Time period	First EF drop	Time period
Mean		2.5	53.2	2.4	195.7	2.1	274.8
SE Mean		0.4	20.2	0.4	23.9	0.4	25.4
Median		2	9	2	131	0	259
SD		3.1	99.0	3.0	131.0	3.1	127.0
Variance		9.4	9810.2	9.1	17164.9	9.8	16124.8
Range		16	429	16	458	16	438
Minimum		0	1	0	60	0	76
Maximum		16	430	16	518	16	514
Percentiles	25	0	2.3	0.0	108.5	0	174.5
	33	1	3.0	0.0	112.0	0	202.9
	50	2	9.0	2.0	131.0	0	259.0
	67	5	24.5	4.2	221.5	2	359.2
	75	5	73.0	5.0	281.8	5	376.5

Back to the Article

Early Echocardiography and ECG Changes Following Radiotherapy in Patients with Stage II-III HER2-Positive Breast Cancer Treated with Anthracycline-Based Chemotherapy with or without Trastuzumab-Based Therapy

Your Privacy